{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T01:30:27Z","timestamp":1792287027420,"version":"4.4.0"},"reference-count":48,"publisher":"Walter de Gruyter GmbH","issue":"0","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,5]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Diazepam is one of the most commonly prescribed tranquilizers for therapy of alcohol withdrawal syndrome (AWS). Despite its popularity, there is currently no precise information on the effect of genetic polymorphisms on its efficacy and safety. The objective of our study was to investigate the effect of CYP2C19*2 and CYP2C19*17 genetic polymorphisms on the efficacy and safety of diazepam in patients with AWS.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n The study was conducted on 30 Russian male patients suffering from the AWS who received diazepam in injections at a dosage of 30.0 mg\/day for 5 days. The efficacy and safety assessment was performed using psychometric scales and scales for assessing the severity of adverse drug reactions.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Based on the results of the study, we revealed the differences in the efficacy of therapy in patients with different CYP2C19 681G>A (\n CYP2C19*2<\/jats:italic>\n ,\n rs4244285<\/jats:italic>\n ) genotypes: (\n CYP2C19*1\/*1<\/jats:italic>\n ) \u22128.5 [\u221215.0; \u22125.0], (\n CYP2C19*1\/*2<\/jats:italic>\n and\n CYP2C19*2\/*2<\/jats:italic>\n ) \u221212.0 [\u221213.0; \u22129.0], p = 0.021. The UKU scale scores, which were used to evaluate the safety of therapy, were also different: (\n CYP2C19*1\/*1<\/jats:italic>\n ) 7.0 [6.0; 12.0], (\n CYP2C19*1\/*2<\/jats:italic>\n and\n CYP2C19*2\/*2<\/jats:italic>\n ) 9.5 [8.0; 11.0], p = 0.009. Patients carrying different CYP2C19 \u2013806C>T (\n CYP2C19*17<\/jats:italic>\n ,\n rs12248560<\/jats:italic>\n ) genotypes also demonstrated differences in therapy efficacy and safety rates.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Thus, the effects of CYP2C19*2 and CYP2C19*17 genetic polymorphisms on the efficacy of diazepam were demonstrated.<\/jats:p>\n <\/jats:sec>","DOI":"10.1515\/dmpt-2019-0026","type":"journal-article","created":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T04:03:44Z","timestamp":1583381024000},"source":"Crossref","is-referenced-by-count":10,"title":["How do CYP2C19*2 and CYP2C19*17 genetic polymorphisms affect the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome?"],"prefix":"10.1515","volume":"0","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4942-8556","authenticated-orcid":false,"given":"Valentin Yu","family":"Skryabin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail S.","family":"Zastrozhin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco V.","family":"Torrado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena A.","family":"Grishina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina A.","family":"Ryzhikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valery V.","family":"Shipitsyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana E.","family":"Galaktionova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander S.","family":"Sorokin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeny A.","family":"Bryun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry A.","family":"Sychev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","reference":[{"key":"ref421","first-page":"1","article-title":"The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"334","year":"1987","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2125.1996.tb00010.x","article-title":"The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype","volume":"42","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1365-2125.1994.tb04336.x","article-title":"Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms","volume":"38","year":"1994","journal-title":"Br J Clin Pharmacol"},{"key":"ref111","first-page":"133","article-title":"Diazepam metabolism by cDNA-expressed human 2C P450s: identification of P4502C18 and P4502C19 as low K(M) diazepam N-demethylases","volume":"25","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/JCP.0000000000000340","article-title":"Extreme duration of diazepam-associated sedation in a patient with alcohol delirium and CYP2C19 polymorphisms","volume":"35","year":"2015","journal-title":"J Clin Psychopharmacol"},{"key":"ref11","first-page":"61","article-title":"Complications of alcohol withdrawal: pathophysiological insights","volume":"22","year":"1998","journal-title":"Alcohol Health Res World"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2125.1996.tb00010.x","article-title":"The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype","volume":"42","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"ref451","first-page":"1","article-title":"The influence of CYP3A5 polymorphisms on haloperidol treatment in patients with alcohol addiction","volume":"11","year":"2018","journal-title":"Pharmacogenomics Pers Med"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1080\/15563650.2018.1542701","article-title":"Effect of early and focused benzodiazepine therapy on length of stay in severe alcohol withdrawal syndrome","volume":"57","year":"2019","journal-title":"Clin Toxicol (Phila)"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"7398","DOI":"10.1158\/1078-0432.CCR-05-0520","article-title":"Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients","volume":"11","year":"2005","journal-title":"Clin Cancer Res"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/106002809402800114","article-title":"Alcohol withdrawal: what is the benzodiazepine of choice?","volume":"28","year":"1994","journal-title":"Ann Pharmacother"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/CCM.0b013e3181ec5412","article-title":"Alcohol withdrawal syndromes in the intensive care unit","volume":"38","year":"2010","journal-title":"Crit Care Med"},{"key":"ref221","first-page":"129","article-title":"Genotyping and phenotyping of CYP2D6 and CYP3A isoenzymes in patients with alcohol use disorder: correlation with haloperidol plasma concentration","volume":"32","year":"2017","journal-title":"Drug Metab Pers Ther"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1097\/01.CCM.0000256841.28351.80","article-title":"A strategy of escalating doses of benzodiazepines and phenobarbital administration reduces the need for mechanical ventilation in delirium tremens","volume":"35","year":"2007","journal-title":"Crit Care Med"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1365-2710.2007.00829.x","article-title":"Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines","volume":"32","year":"2007","journal-title":"J Clin Pharm Ther"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1097\/FPC.0b013e32833225e7","article-title":"The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test","volume":"19","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"ref261","first-page":"VE01","article-title":"Alcohol withdrawal syndrome: benzodiazepines and beyond","volume":"9","year":"2015","journal-title":"J Clin Diagn Res"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.drugalcdep.2018.08.017","article-title":"Predictors of resistant alcohol withdrawal (RAW): a retrospective case-control study","volume":"192","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1365-2710.2007.00829.x","article-title":"Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines","volume":"32","year":"2007","journal-title":"J Clin Pharm Ther"},{"key":"ref181","first-page":"1","article-title":"The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"334","year":"1987","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1021\/cn5000056","article-title":"Classics in chemical neuroscience: diazepam (valium)","volume":"5","year":"2014","journal-title":"ACS Chem Neurosci"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/JCP.0000000000000340","article-title":"Extreme duration of diazepam-associated sedation in a patient with alcohol delirium and CYP2C19 polymorphisms","volume":"35","year":"2015","journal-title":"J Clin Psychopharmacol"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40263-016-0403-y","article-title":"Diazepam in the treatment of moderate to severe alcohol withdrawal","volume":"31","year":"2017","journal-title":"CNS Drugs"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1365-2125.1994.tb04336.x","article-title":"Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms","volume":"38","year":"1994","journal-title":"Br J Clin Pharmacol"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2147\/PGPM.S140700","article-title":"Pharmacodynamic genetic polymorphisms affect adverse drug reactions of haloperidol in patients with alcohol-use disorder","volume":"10","year":"2017","journal-title":"Pharmacogenomics Pers Med"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.drugalcdep.2018.08.017","article-title":"Predictors of resistant alcohol withdrawal (RAW): a retrospective case-control study","volume":"192","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"ref171","first-page":"21","article-title":"Utilizing CIWA-Ar to assess use of benzodiazepines in patients vulnerable to alcohol withdrawal syndrome","volume":"100","year":"2004","journal-title":"W V Med J"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40263-016-0403-y","article-title":"Diazepam in the treatment of moderate to severe alcohol withdrawal","volume":"31","year":"2017","journal-title":"CNS Drugs"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"7398","DOI":"10.1158\/1078-0432.CCR-05-0520","article-title":"Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients","volume":"11","year":"2005","journal-title":"Clin Cancer Res"},{"key":"ref211","first-page":"1","article-title":"The influence of CYP3A5 polymorphisms on haloperidol treatment in patients with alcohol addiction","volume":"11","year":"2018","journal-title":"Pharmacogenomics Pers Med"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1097\/FPC.0b013e32833225e7","article-title":"The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test","volume":"19","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"ref461","first-page":"129","article-title":"Genotyping and phenotyping of CYP2D6 and CYP3A isoenzymes in patients with alcohol use disorder: correlation with haloperidol plasma concentration","volume":"32","year":"2017","journal-title":"Drug Metab Pers Ther"},{"key":"ref351","first-page":"133","article-title":"Diazepam metabolism by cDNA-expressed human 2C P450s: identification of P4502C18 and P4502C19 as low K(M) diazepam N-demethylases","volume":"25","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00228-016-2061-x","article-title":"Role of CYP2C19 gene polymorphism in acute alcohol withdrawal treatment with loading dose of diazepam in a South Indian population","volume":"72","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/106002809402800114","article-title":"Alcohol withdrawal: what is the benzodiazepine of choice?","volume":"28","year":"1994","journal-title":"Ann Pharmacother"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2147\/PGPM.S140700","article-title":"Pharmacodynamic genetic polymorphisms affect adverse drug reactions of haloperidol in patients with alcohol-use disorder","volume":"10","year":"2017","journal-title":"Pharmacogenomics Pers Med"},{"key":"ref251","first-page":"61","article-title":"Complications of alcohol withdrawal: pathophysiological insights","volume":"22","year":"1998","journal-title":"Alcohol Health Res World"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1080\/15563650.2018.1542701","article-title":"Effect of early and focused benzodiazepine therapy on length of stay in severe alcohol withdrawal syndrome","volume":"57","year":"2019","journal-title":"Clin Toxicol (Phila)"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1021\/cn5000056","article-title":"Classics in chemical neuroscience: diazepam (valium)","volume":"5","year":"2014","journal-title":"ACS Chem Neurosci"},{"key":"ref21","first-page":"VE01","article-title":"Alcohol withdrawal syndrome: benzodiazepines and beyond","volume":"9","year":"2015","journal-title":"J Clin Diagn Res"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00228-005-0032-8","article-title":"Pharmacokinetics and pharmacodynamics of etizolam are influenced by polymorphic CYP2C19 activity","volume":"61","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00228-016-2061-x","article-title":"Role of CYP2C19 gene polymorphism in acute alcohol withdrawal treatment with loading dose of diazepam in a South Indian population","volume":"72","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/CCM.0b013e3181ec5412","article-title":"Alcohol withdrawal syndromes in the intensive care unit","volume":"38","year":"2010","journal-title":"Crit Care Med"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1097\/01.CCM.0000256841.28351.80","article-title":"A strategy of escalating doses of benzodiazepines and phenobarbital administration reduces the need for mechanical ventilation in delirium tremens","volume":"35","year":"2007","journal-title":"Crit Care Med"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0006-2952(97)00558-3","article-title":"Role of cDNA-expressed human cytochromes P450 in the metabolism of diazepam","volume":"55","year":"1998","journal-title":"Biochem Pharmacol"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0006-2952(97)00558-3","article-title":"Role of cDNA-expressed human cytochromes P450 in the metabolism of diazepam","volume":"55","year":"1998","journal-title":"Biochem Pharmacol"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00228-005-0032-8","article-title":"Pharmacokinetics and pharmacodynamics of etizolam are influenced by polymorphic CYP2C19 activity","volume":"61","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"ref411","first-page":"21","article-title":"Utilizing CIWA-Ar to assess use of benzodiazepines in patients vulnerable to alcohol withdrawal syndrome","volume":"100","year":"2004","journal-title":"W V Med J"}],"container-title":["Drug Metabolism and Personalized Therapy"],"original-title":[],"link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/dmdi.ahead-of-print\/dmpt-2019-0026\/dmpt-2019-0026.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/dmpt-2019-0026\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T17:52:25Z","timestamp":1619027545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/dmpt-2019-0026\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,5]]},"references-count":48,"journal-issue":{"issue":"0"},"URL":"https:\/\/doi.org\/10.1515\/dmpt-2019-0026","relation":{},"ISSN":["2363-8915"],"issn-type":[{"value":"2363-8915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,5]]}}}